Seyed Alireza Javadinia, V, shared an article by Paolo Bossi, et al. on LinkedIn:
“The I-TACKLE trial by Paolo Bossi; Immunotherapy followed by cetuximab in locally advanced/metastatic cutaneous SCC:
Median treatment durations were 3 months (pembrolizumab) and 4 months (combination).
Highlights:
1. Cetuximab overcame pembrolizumab resistance, reaching a 63 % cumulative ORR.
2. Cetuximab reversed primary/acquired resistance in 43 % of cSCC cases, with safety.”
Immunotherapy followed by cetuximab in locally advanced/metastatic cutaneous squamous cell carcinomas: the I-TACKLE trial.
Authors: Paolo Bossi, et al.
